A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.

Source:http://linkedlifedata.com/resource/pubmed/id/17360479

Proc. Natl. Acad. Sci. U.S.A. 2007 Mar 6 104 10 4071-6

Download in:

View as

Triples

General Info

PMID
17360479